Titan Pharmaceuticals (NASDAQ:TTNP) Receives New Coverage from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a report issued on Thursday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Up 1.2 %

Shares of NASDAQ:TTNP opened at $6.82 on Thursday. Titan Pharmaceuticals has a fifty-two week low of $5.00 and a fifty-two week high of $16.60. The company has a market cap of $6.23 million, a PE ratio of -0.83 and a beta of 1.32. The company’s 50-day moving average price is $7.19 and its 200 day moving average price is $7.02.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.